Thrivent Financial for Lutherans Has $485,000 Stock Position in Incyte Co. (NASDAQ:INCY)

Thrivent Financial for Lutherans trimmed its position in shares of Incyte Co. (NASDAQ:INCY) by 1.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,332 shares of the biopharmaceutical company’s stock after selling 143 shares during the period. Thrivent Financial for Lutherans’ holdings in Incyte were worth $485,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Greenwood Capital Associates LLC acquired a new stake in shares of Incyte during the 3rd quarter worth approximately $433,000. Andra AP fonden raised its position in Incyte by 35.2% in the second quarter. Andra AP fonden now owns 247,800 shares of the biopharmaceutical company’s stock worth $15,022,000 after purchasing an additional 64,500 shares in the last quarter. SG Americas Securities LLC lifted its stake in Incyte by 54.0% during the second quarter. SG Americas Securities LLC now owns 67,936 shares of the biopharmaceutical company’s stock worth $4,118,000 after purchasing an additional 23,817 shares during the period. Diversified Trust Co boosted its holdings in Incyte by 45.3% during the second quarter. Diversified Trust Co now owns 52,398 shares of the biopharmaceutical company’s stock valued at $3,176,000 after purchasing an additional 16,336 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its stake in shares of Incyte by 5.9% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 1,265,966 shares of the biopharmaceutical company’s stock valued at $83,680,000 after purchasing an additional 70,596 shares during the period. Institutional investors and hedge funds own 96.97% of the company’s stock.

Insider Activity at Incyte

In other Incyte news, EVP Jonathan Elliott Dickinson sold 8,450 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $62.36, for a total value of $526,942.00. Following the transaction, the executive vice president now owns 36,390 shares of the company’s stock, valued at approximately $2,269,280.40. The trade was a 18.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Thomas Tray sold 572 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $62.94, for a total transaction of $36,001.68. Following the transaction, the insider now owns 24,825 shares of the company’s stock, valued at approximately $1,562,485.50. The trade was a 2.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,745 shares of company stock worth $1,311,687 over the last ninety days. Insiders own 17.60% of the company’s stock.

Incyte Stock Performance

NASDAQ:INCY opened at $74.92 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.82 and a current ratio of 1.87. The company has a market cap of $14.43 billion, a price-to-earnings ratio of 535.18, a PEG ratio of 8.30 and a beta of 0.69. The stock has a fifty day moving average price of $71.53 and a 200-day moving average price of $65.57. Incyte Co. has a fifty-two week low of $50.35 and a fifty-two week high of $83.95.

Incyte (NASDAQ:INCY) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.07 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.12). The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.08 billion. Incyte had a negative return on equity of 0.63% and a net margin of 0.80%. The firm’s revenue was up 23.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.91 EPS. As a group, equities analysts anticipate that Incyte Co. will post 0.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

INCY has been the subject of a number of research analyst reports. Royal Bank of Canada lifted their target price on shares of Incyte from $72.00 to $80.00 and gave the company a “sector perform” rating in a research note on Thursday, November 14th. William Blair reiterated an “outperform” rating on shares of Incyte in a research report on Monday, September 9th. BMO Capital Markets reaffirmed an “underperform” rating and issued a $52.00 target price (up from $48.00) on shares of Incyte in a research note on Wednesday, October 30th. Wells Fargo & Company lifted their price target on shares of Incyte from $62.00 to $68.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Finally, Oppenheimer upped their price objective on shares of Incyte from $81.00 to $82.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Incyte has a consensus rating of “Hold” and a consensus price target of $77.16.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.